Research across Cancer
Related studies from across the Cancer family.
Bispecific antibodies improve progression-free survival and overall survival in patients with solid tumors
Bispecific antibodies improve survival for patients with solid tumors
This meta-analysis of 3505 patients with solid tumors found that bispecific antibodies significantly improved progression-free survival (HR …
A new type of antibody treatment shows promise in extending life and slowing cancer growth for patients with solid tumors.
High Siglec-15 Tumor Expression Tied to Worse Survival
High Levels of Siglec-15 Protein Linked to Shorter Survival in Solid Tumors
Meta-analysis of 4,075 patients shows high tumoral Siglec-15 expression is linked to poorer overall survival (HR 1.53).
Doctors found that high levels of a specific protein called Siglec-15 are linked to worse outcomes for patients with solid tumors.
Approximately 61% of cancer patients resume anticancer treatment after unplanned ICU admission
Most cancer patients do not resume treatment after ICU stay
This meta-analysis of 3551 patients with solid tumors or hematological malignancies found that 61% of patients resumed any anticancer treatm…
Only about 60% of cancer patients resume any treatment after an unplanned ICU stay, highlighting a critical gap in care after a medical cris…
Bispecific antibodies improve progression-free survival and overall survival in patients with solid tumors
Bispecific Antibodies Show Improved Survival for Solid Tumors
This meta-analysis of 3,505 patients with solid tumors found that bispecific antibodies significantly improved progression-free survival (HR…
New analysis suggests bispecific antibodies may improve survival and slow tumor growth for patients with solid tumors compared to other trea…
Engineered nanobodies offer programmable platform to overcome limitations of conventional antibodies in angiogenic diseases
Engineered nanobodies may offer better ways to treat solid tumors
This systematic review examines engineered nanobodies targeting angiogenesis-related pathways for solid tumors and other conditions like wet…
Tiny engineered proteins called nanobodies could overcome the limitations of standard treatments for solid tumors and other blood vessel-rel…
Elevated pretreatment pan-immune-inflammation value correlates with worse survival outcomes in patients treated with immune checkpoint inhibitors
High inflammation levels may signal poorer survival for cancer patients
This systematic review and meta-analysis of 3,272 participants across 28 cohorts found that elevated pretreatment PIV is associated with sho…
A new look at cancer data suggests that high inflammation scores before treatment can predict shorter survival for those using immune checkp…
Natural polysaccharides combined with immune checkpoint inhibitors show synergistic benefits in preclinical and early clinical observations
Natural sugars may help patients whose cancer resists immune drugs
This systematic review examines the use of natural polysaccharides as immune adjuvants for patients with solid tumors resistant to immune ch…
New research explores how natural polysaccharides can help boost the effectiveness of immunotherapy for patients with advanced solid tumors.
TET2 functions as a tumor suppressor in myeloid malignancies and immunomodulator in solid tumors
TET2 protein acts as a key regulator in several diseases
This systematic review examines the role of TET2 across various conditions including hematological malignancies, solid tumors, and inflammat…
A key protein called TET2 helps control cell behavior and may play a major role in treating cancer and inflammatory conditions.
T cell signaling and metabolic rewiring are critical for T cell engager efficacy in solid tumors
New research explores how cell metabolism affects cancer treatments
This mini-review explores the roles of T cell signaling and metabolism in T cell engagers (TCEs) for solid tumors and hematologic malignanci…
Scientists are looking at how the energy and nutrients inside immune cells impact the success of new cancer therapies.
IEN plus NACT shows greatest improvement in CD4+ counts among ranked strategies
New research identifies ways to protect immune cells during cancer surgery
This network meta-analysis of 82 RCTs evaluates multimodal interventions to maintain T lymphocyte subsets in patients with solid tumors unde…
A new analysis shows that combining specific nutrition and therapies can help maintain vital immune cell levels for patients undergoing soli…
KRAS G12C inhibitors improve progression-free survival with HR 0.62 in KRASG12C-mutated solid tumors
New drugs show promise for patients with specific tumor mutations
This meta-analysis of 3 RCTs involving 949 patients evaluated KRAS G12C inhibitors for solid tumors. The analysis found a significant improv…
A new class of drugs shows promise in slowing the growth of certain solid tumors for patients with a specific genetic mutation.
Synergistic Effects of Immune Checkpoint Inhibitors and Radiotherapy in Solid Tumor Management
Combining immune checkpoint inhibitors and radiotherapy improves survival outcomes
Meta-analysis data indicates that combining immune checkpoint inhibitors with radiotherapy significantly improves survival outcomes in solid…
New data shows that adding immune checkpoint inhibitors to radiation therapy can improve survival for patients with many types of solid tumo…